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Abstract: Human chymotrypsin-like elastases 3A and 3B (CELA3A and CELA3B) are the products of
gene duplication and share 92% identity in their primary structure. CELA3B forms stable complexes
with procarboxypeptidases A1 and A2 whereas CELA3A binds poorly due to the evolutionary
substitution of Ala241 with Gly in exon 7. Since position 241 is polymorphic both in CELA3A
(p.G241A) and CELA3B (p.A241G), genetic analysis can directly assess whether individual variability
in complex formation might alter risk for chronic pancreatitis. Here we sequenced exon 7 of CELA3A
and CELA3B in a cohort of 225 subjects with chronic pancreatitis (120 alcoholic and 105 non-alcoholic)
and 300 controls of Hungarian origin. Allele frequencies were 2.5% for CELA3A p.G241A and 1.5%
for CELA3B p.A241G in controls, and no significant difference was observed in patients. Additionally,
we identified six synonymous variants, two missense variants, a gene conversion event and ten
variants in the flanking intronic regions. Variant c.643-7G>T in CELA3B showed an association
with alcoholic chronic pancreatitis with a small protective effect (OR = 0.59, 95% CI = 0.39–0.89,
p = 0.01). Functional analysis of missense variants revealed no major defects in secretion or activity.
We conclude that variants affecting amino-acid position 241 in CELA3A and CELA3B are not associated
with chronic pancreatitis, indicating that changes in complex formation between proelastases and
procarboxypeptidases do not alter pancreatitis risk.
Keywords: pancreas; chronic pancreatitis; digestive protease; zymogen complexes; elastase
1. Introduction
Chronic pancreatitis (CP) is a progressive, relapsing inflammatory disorder of the pancreas which
often develops in the background of genetic susceptibility [1–3]. Mutations in the best characterized
risk genes PRSS1 (cationic trypsinogen), SPINK1 (pancreatic secretory trypsin inhibitor), and CTRC
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(chymotrypsin C) stimulate activation of trypsinogen and result in elevated trypsin activity in the
pancreas [4–9]. More recently, loss-of-function variants in the CPA1 gene encoding carboxypeptidase
A1 were shown to increase risk for early onset CP [10]. The majority of impaired CPA1 variants
exhibited a secretion defect due to intracellular misfolding and retention. The mechanism of action
of CPA1 variants was unrelated to trypsinogen activation or trypsin activity and seemed to involve
endoplasmic reticulum stress as a consequence of misfolding [10]. However, it is also possible that
reduced CPA1 secretion might cause predisposition to CP by other mechanisms. In this respect,
we noted that procarboxypeptidase A (proCPA) often forms complexes with proelastases in the
mammalian pancreas ([11] and references therein). Consequently, changes in CPA1 levels in the
secretory pathway and pancreatic juice might have a significant impact on proelastases; possibly
facilitating ectopic elastase activation and thereby contributing to pancreatic injury.
The human chymotrypsin-like elastase (CELA) family is encoded by five genes: CELA1, CELA2A,
CELA2B, CELA3A and CELA3B. Due to evolutionary mutations, CELA1 is not expressed in the human
pancreas and CELA2B is an inactive protease [12–14]. CELA2A and CELA3B bind to proCPA1 and
CELA3B also binds to proCPA2 [11,15–17]. Even though CELA3A is 92% identical with CELA3B in
its primary structure, it does not form tight complexes with proCPA1 or proCPA2 [11]. We found
that a major determinant of binding affinity was amino acid 241, which is Gly in CELA3A and Ala in
CELA3B. Mutation p.G241A in CELA3A increases whereas mutation p.A241G in CELA3B reduces
binding to proCPA1 [11]. Notably, position 241 is polymorphic in both elastases with minor allele
frequencies of about 2% in subjects of European origin. This genetic variation should translate to
individual differences in complex formation between proelastases and proCPA1. More importantly,
the polymorphic nature of amino-acid 241 offers the unique opportunity to perform a genetic
association study to investigate whether changes in complex formation between proelastases and
procarboxypeptidases affect CP risk. To this end, in the present paper we compared allele frequencies
of variants p.G241A in CELA3A and p.A241G in CELA3B between subjects with CP and controls
without pancreatic disease.
2. Results
2.1. DNA Sequence Analysis of Exon 7 of Human CELA3A and CELA3B
To investigate whether changes in complex formation between human procarboxypeptidases
and proelastases alter risk for CP, we investigated the frequency of variants c.722G>C (p.G241A) in
CELA3A and c.722C>G (p.A241G) in CELA3B in subjects with CP and controls without pancreatic
disease. We sequenced exon 7 and flanking intronic regions of CELA3A and CELA3B in 225 patients
and 300 controls from the registry of the Hungarian Pancreatic Study Group. This CP cohort consisted
of 120 alcoholic chronic pancreatitis (ACP) and 105 idiopathic chronic pancreatitis (ICP) patients.
Sequence analysis of CELA3A and CELA3B was successfully completed for all patient samples and
for 295 and 293 of the 300 control samples, respectively. In CELA3A we found 8 variants which
included 4 intronic variants, 3 synonymous variants and 1 non-synonymous (missense) variant
(Table 1). Synonymous variants c.750C>T (p.P250=) and c.753G>A (p.T251=) were found in complete
linkage disequilibrium. In CELA3B we detected 13 variants which included 6 intronic variants,
3 synonymous variants, 3 non-synonymous (missense) variants and a gene-conversion event resulting
in five nucleotide alterations that changed three amino-acids at the protein level (Table 1). Synonymous
variants c.699T>C (p.H233=) and c.702C>T (p.G234=) were found in the same ACP patient.
When allele frequency was considered, distribution of the variants between patients and controls
showed a significant difference only for the CELA3B variant c.643-7G>T in intron 6, which occurred
with an allele frequency of 16% in patients and 21.3% in controls (OR = 0.7; 95% CI 0.51–0.97; p = 0.03;
Table 1). Subgroup analysis revealed that the association was driven by the ACP cohort (OR = 0.59,
95% CI = 0.39–0.89, p = 0.01) while it was not significant in ICP patients (p = 0.4; Tables 2 and 3).
Importantly, neither p.G241A in CELA3A nor p.A241G in CELA3B was significantly enriched in
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patients or controls. Novel missense variants identified in CELA3B were rare; the heterozygous
c.694G>C (p.V232L) variant was found in one ACP patient and one control, whereas the heterozygous
c.740G>C (p.R247P) variant was found in one control subject only. Both subjects with the p.V232L
variant also carried a heterozygous c.643-7G>T CELA3B variant, while the subject with the p.R247P
variant carried a heterozygous c.643-26C>T CELA3B variant. An unexpected observation in CELA3B
was a heterozygous gene conversion event detected in a patient with ICP. A minimum of seven
nucleotides in CELA3B between c.736 and c.742 was converted with the corresponding CELA3A
sequence. This resulted in five nucleotide changes (c.736A>T, c.737C>T c.739C>A, c.740G>T, c.742A>T)
and three amino-acid changes (p.T246F, p.R247I, p.R248W) in CELA3B (Figure 1).
Genotypes were also analyzed for common variants using dominant and recessive models but no
significant differences were found between CP patients and controls (Table 4). In subgroup analysis
of variant c.643-7G>T genotypes using a dominant model (GT plus TT in patients versus controls)
we confirmed the underrepresentation of this variant in ACP patients (OR = 0.6, 95% CI 0.37–0.96,
p = 0.03), whereas the same association could not be verified in the ICP group (p = 0.52) (Tables 5 and 6).
Using a recessive model (TT genotypes in patients versus controls) a more obvious difference was
observed in the ACP group (1.7%) than in ICP patients (3.8%) versus controls (5.8%), however, due to
the limited sample size it did not reach statistical significance (Tables 5 and 6).
In summary, with the exception of the apparently protective c.643-7G>T CELA3B variant,
we found no other association of CELA3A and CELA3B variants with CP or disease subgroups ACP
and ICP. Importantly, the lack of association between variants at amino-acid position 241 and CP
indicates that changes in complex formation between proelastases and procarboxypeptidases have no
appreciable effect on the risk of CP.
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variations are indicated by arrows. Alignment of the relevant sequence tracts of CELA3A and CELA3B 
are also shown. CELA, human chymotrypsin-like elastase. 
 
Figure 1. Gene conversion between CELA3A (donor) and CELA3B (acceptor). Electropherogram of
CELA3B exon 7 in the Hungarian idiopathic chronic pancreatitis (ICP) patient. Heterozygous variations
are indicated by arrows. Alignment of the relevant sequence tracts of CELA3A and CELA3B are also
shown. CELA, human chymotrypsin-like elastase.
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Table 1. Allele frequency of CELA3A and CELA3B variants in patients with chronic pancreatitis and controls without pancreatic disease. Variants affecting position 241
are highlighted in bold. OR, odds ratio; CI, confidence interval. Asterisk indicates significant association.
CELA3A Nucleotide Change Amino Acid Change Patient Alleles Control Alleles OR p Value 95% CI
Intron 6 c.643-78T>C – 81/450 (18%) 124/590 (21%) 0.83 0.23 0.60–1.13
Intron 6 c.643-17delC – 21/450 (4.7%) 24/590 (4.1%) 1.15 0.64 0.63–2.1
Intron 6 c.643-13_12delCT – 3/450 (0.7%) 5/590 (0.8%) 0.79 0.74 0.19–3.3
Exon 7 c.699C>T p.H233= 1/450 (0.2%) 0/590 (0%) – – –
Exon 7 c.722G>C p.G241A 9/450 (2%) 15/590 (2.5%) 0.78 0.57 0.34–1.8
Exon 7 c.750C>T p.P250= 105/450 (23.3%) 157/590 (26.6%) 0.84 0.23 0.63–1.12
Exon 7 c.753G>A p.T251= 105/450 (23.3%) 157/590 (26.6%) 0.84 0.23 0.63–1.12
Intron 7 c.795+21C>A 321/450 (71.3%) 399/590 (67.6%) 1.19 0.2 0.91–1.56
CELA3B Nucleotide Change Amino Acid Change Patient Alleles Control Alleles OR p Value 95% CI
Intron 6 c.643-26C>T – 20/450 (4.4%) 25/586 (4.3%) 1.04 0.89 0.57–1.91
Intron 6 c.643-9C>T – 2/450 (0.4%) 0/586 (0%) – – –
Intron 6 c.643-7G>T – 72/450 (16%) 125/586 (21.3%) 0.7 0.03 * 0.51–0.97
Exon 7 c.694G>C p.V232L 1/450 (0.2%) 1/586 (0.2%) 1.3 0.85 0.08–20.88
Exon 7 c.699T>C p.H233= 1/450 (0.2%) 0/586 (0%) – – –
Exon 7 c.702C>T p.G234= 1/450 (0.2%) 0/586 (0%) – – –
Exon 7 c.722C>G p.A241G 10/450 (2.2%) 9/586 (1.5%) 1.46 0.42 0.59–3.61
Exon 7 c.736A>T, c.737C>T, c.739C>A, c.740G>T, c.742A>T p.T246F, p.R247I, p.R248W 1/450 (0.2%) 0/586 (0%) – – –
Exon 7 c.740G>C p.R247P 0/450 (0%) 1/586 (0.2%) – – –
Exon 7 c.780T>C p.I260= 445/450 (98.9%) 580/586 (99%) 0.92 0.89 0.28–3.03
Intron 7 c.795+21C>A – 340/450 (75.6%) 413/586 (70.5%) 1.29 0.07 0.97–1.71
Intron 7 c.795+22G>A – 1/450 (0.2%) 1/586 (0.2%) 1.3 0.85 0.08–20.88
Intron 7 c.795+73G>A – 0/450 (0%) 1/586 (0.2%) – – –
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Table 2. Allele frequency of CELA3A and CELA3B variants in patients with alcoholic chronic pancreatitis (ACP) and controls without pancreatic disease. Variants
affecting position 241 are highlighted in bold. OR, odds ratio; CI, confidence interval. Asterisk indicates significant association.
CELA3A Nucleotide Change Amino Acid Change ACP Patient Alleles Control Alleles OR p Value 95% CI
Intron 6 c.643-78T>C – 43/240 (17.9%) 124/590 (21%) 0.82 0.31 0.56–1.2
Intron 6 c.643-17delC – 13/240 (5.4%) 24/590 (4.1%) 1.35 0.4 0.68–2.7
Intron 6 c.643-13_12delCT – 1/240 (0.4%) 5/590 (0.8%) 0.49 0.52 0.06–4.21
Exon 7 c.722G>C p.G241A 4/240 (1.7%) 15/590 (2.5%) 0.65 0.45 0.21–1.98
Exon 7 c.750C>T p.P250= 57/240 (23.8%) 157/590 (26.6%) 0.86 0.4 0.60–1.22
Exon 7 c.753G>A p.T251= 57/240 (23.8%) 157/590 (26.6%) 0.86 0.4 0.60–1.22
Intron 7 c.795+21C>A – 167/240 (69.6%) 399/590 (67.6%) 1.1 0.58 0.79–1.51
CELA3B Nucleotide Change Amino Acid Change ACP Patient Alleles Control Alleles OR p Value 95% CI
Intron 6 c.643-26C>T – 13/240 (5.4%) 25/586 (4.3%) 1.29 0.48 0.65–2.56
Intron 6 c.643-9C>T – 2/240 (0.8%) 0/586 (0%) – – –
Intron 6 c.643-7G>T – 33/240 (13.8%) 125/586 (21.3%) 0.59 0.01 * 0.39–0.89
Exon 7 c.694G>C p.V232L 1/240 (0.4%) 1/586 (0.2%) 2.45 0.53 0.15–39.29
Exon 7 c.699T>C p.H233= 1/240 (0.4%) 0/586 (0%) – – –
Exon 7 c.702C>T p.G234= 1/240 (0.4%) 0/586 (0%) – – –
Exon 7 c.722C>G p.A241G 5/240 (2.1%) 9/586 (1.5%) 1.37 0.58 0.45–4.11
Exon 7 c.780T>C p.I260= 237/240 (98.8%) 580/586 (99%) 0.82 0.78 0.20–3.29
Intron 7 c.795+21C>A – 179/240 (74.6%) 413/586 (70.5%) 1.23 0.24 0.88–1.73
Intron 7 c.795+22G>A – 1/240 (0.4%) 1/586 (0.2%) 2.45 0.53 0.15–39.29
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Table 3. Allele frequency of CELA3A and CELA3B variants in patients with idiopathic chronic pancreatitis (ICP) and controls without pancreatic disease. Variants
affecting position 241 are highlighted in bold. OR, odds ratio; CI, confidence interval.
CELA3A Nucleotide Change Amino Acid Change ICP Patient Alleles Control Alleles OR p Value 95% CI
Intron 6 c.643-78T>C – 38/210 (18.1%) 124/590 (21%) 0.83 0.37 0.56–1.24
Intron 6 c.643-17delC – 8/210 (3.8%) 24/590 (4.1%) 0.93 0.87 0.42–2.11
Intron 6 c.643-13_12delCT – 2/210 (1%) 5/590 (0.8%) 1.13 0.89 0.22–5.84
Exon 7 c.699C>T p.H233= 1/210 (0.5%) 0/590 (0%) – – –
Exon 7 c.722G>C p.G241A 5/210 (2.4%) 15/590 (2.5%) 0.93 0.89 0.34–2.61
Exon 7 c.750C>T p.P250= 48/210 (22.9%) 157/590 (26.6%) 0.82 0.29 0.56–1.18
Exon 7 c.753G>A p.T251= 48/210 (22.9%) 157/590 (26.6%) 0.82 0.29 0.56–1.18
Intron 7 c.795+21C>A – 154/210 (73.3%) 399/590 (67.6%) 1.32 0.13 0.93–1.87
CELA3B Nucleotide Change Amino Acid Change ICP Patient Alleles Control Alleles OR p Value 95% CI
Intron 6 c.643-26C>T – 7/210 (3.3%) 25/586 (4.3%) 0.77 0.56 0.33–1.82
Intron 6 c.643-7G>T – 39/210 (18.6%) 125/586 (21.3%) 0.84 0.4 0.56–1.26
Exon 7 c.722C>G p.A241G 5/210 (2.4%) 9/586 (1.5%) 1.56 0.43 0.52–4.72
Exon 7 c.736A>T, c.737C>T, c.739C>A, c.740G>T, c.742A>T p.T246F, p.R247I, p.R248W 1/210 (0.5%) 0/586 (0%) – – –
Exon 7 c.780T>C p.I260= 208/210 (99%) 580/586 (99%) 1.08 0.93 0.22–5.37
Intron 7 c.795+21C>A – 161/210 (76.7%) 413/586 (70.5%) 1.38 0.09 0.96–1.98
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Table 4. Genotype distribution of common CELA3A and CELA3B variants. Results were analyzed assuming dominant (shown in italics) or recessive models of
inheritance. OR, odds ratio; CI, confidence interval.
CELA3A Nucleotide Change Genotype Patients Controls OR p Value 95% CI
Intron 6 c.643-78T>C
TT 153/225 (68%) 186/295 (63%) – – –
TC 63/225 (28%) 94/295 (31.9%) 0.80 0.25 0.56–1.16
CC 9/225 (4%) 15/295 (5.1%) 0.78 0.56 0.33–1.81
Exon 7 c.750C > T
CC 132/225 (58.7%) 158/295 (53.5%) – – –
CT 81/225 (36%) 117/295 (39.7%) 0.81 0.25 0.57–1.15
TT 12/225 (5.3%) 20/295 (6.8%) 0.77 0.5 0.37–1.62
Exon 7 c.753G > A
GG 132/225 (58.7%) 158/295 (53.5%) – – –
GA 81/225 (36%) 117/295 (39.7%) 0.81 0.25 0.57–1.15
AA 12/225 (5.3%) 20/295 (6.8%) 0.77 0.5 0.37–1.62
Intron 7 c.795+21C>A
CC 17/225 (7.6%) 32/295 (10.8%) – – –
CA 95/225 (42.2%) 127/295 (43.1%) 1.49 0.21 0.80–2.76
AA 113/225 (50.2%) 136/295 (46.1%) 1.18 0.35 0.83–1.67
CELA3B Nucleotide Change Genotype Patients Controls OR p Value 95% CI
Intron 6 c.643-7G>T
GG 159/225 (70.6%) 185/293 (63.1%) – – –
GT 60/225 (26.7%) 91/293 (31.1%) 0.71 0.07 0.49–1.03
TT 6/225 (2.7%) 17/293 (5.8%) 0.44 0.09 0.17–1.15
Exon 7 c.780T>C
TT 1/225 (0.5%) 0/293 (0%) – – –
TC 3/225 (1.3%) 6/293 (2%) – – –
CC 221/225 (98.2%) 287/293 (98%) 1.15 0.83 0.32–4.14
Intron 7 c.795+21C>A
CC 10/225 (4.4%) 24/293 (8.2%) – – –
CA 90/225 (40%) 125/293 (42.7%) 1.92 0.09 0.90–4.1
AA 125/225 (55.6%) 144/293 (49.1%) 1.29 0.15 0.91–1.8
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Table 5. Genotype distribution of common CELA3A and CELA3B variants in patients with alcoholic chronic pancreatitis (ACP) and controls without pancreatic
disease. Results were analyzed assuming dominant (shown in italics) or recessive models of inheritance. OR, odds ratio; CI, confidence interval. Asterisk indicates
significant association.
CELA3A Nucleotide Change Genotype ACP Patients Controls OR p Value 95% CI
Intron 6 c.643-78T>C
TT 83/120 (69.2%) 186/295 (63%) – – –
TC 31/120 (25.8%) 94/295 (31.9%) 0.76 0.24 0.48–1.2
CC 6/120 (5%) 15/295 (5.1%) 0.98 0.97 0.37–2.6
Exon 7 c.750C>T
CC 70/120 (58.3%) 158/295 (53.5%) – – –
CT 43/120 (35.8%) 117/295 (39.7%) 0.82 0.38 0.54–1.27
TT 7/120 (5.9%) 20/295 (6.8%) 0.85 0.72 0.35–2.07
Exon 7 c.753G>A
GG 70/120 (58.3%) 158/295 (53.5%) – – –
GA 43/120 (35.8%) 117/295 (39.7%) 0.82 0.38 0.54–1.27
AA 7/120 (5.9%) 20/295 (6.8%) 0.85 0.72 0.35–2.07
Intron 7 c.795+21C>A
CC 10/120 (8.3%) 32/295 (10.8%) – – –
CA 53/120 (44.2%) 127/295 (43.1%) 1.34 0.44 0.64–2.82
AA 57/120 (47.5%) 136/295 (46.1%) 1.06 0.8 0.69–1.62
CELA3B Nucleotide Change Genotype ACP Patients Controls OR p Value 95% CI
Intron 6 c.643-7G>T
GG 89/120 (74.1%) 185/293 (63.1%) – – –
GT 29/120 (24.2%) 91/293 (31.1%) 0.6 0.03 * 0.37–0.96
TT 2/120 (1.7%) 17/293 (5.8%) 0.28 0.09 0.06–1.21
Exon 7 c.780T>C
TT 1/120 (0.8%) 0/293 (0%) – – –
TC 1/120 (0.8%) 6/293 (2%) – – –
CC 118/120 (98.4%) 287/293 (98%) 1.23 0.8 0.25–6.2
Intron 7 c.795+21C>A
CC 7/120 (5.8%) 24/293 (8.2%) – – –
CA 47/120 (39.2%) 125/293 (42.7%) 1.44 0.41 0.60–3.44
AA 66/120 (55%) 144/293 (49.1%) 1.27 0.28 0.83–1.94
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Table 6. Genotype distribution of common CELA3A and CELA3B variants in patients with idiopathic chronic pancreatitis (ICP). Results were analyzed assuming
dominant (shown in italics) or recessive models of inheritance. OR, odds ratio; CI, confidence interval.
CELA3A Nucleotide Change Genotype ICP Patients Controls OR p Value 95% CI
Intron 6 c.643-78T>C
TT 70/105 (66.6%) 186/295 (63%) – – –
TC 32/105 (30.5%) 94/295 (31.9%) 0.85 0.51 0.53–1.36
CC 3/105 (2.9%) 15/295 (5.1%) 0.55 0.35 0.16–1.94
Exon 7 c.750C>T
CC 62/105 (59%) 158/295 (53.5%) – – –
CT 38/105 (36.2%) 117/295 (39.7%) 0.8 0.33 0.51–1.26
TT 5/105 (4.8%) 20/295 (6.8%) 0.69 0.47 0.25–1.88
Exon 7 c.753G>A
GG 62/105 (59%) 158/295 (53.5%) – – –
GA 38/105 (36.2%) 117/295 (39.7%) 0.8 0.33 0.51–1.26
AA 5/105 (4.8%) 20/295 (6.8%) 0.69 0.47 0.25–1.88
Intron 7 c.795+21C>A
CC 7/105 (6.7%) 32/295 (10.8%) – – –
CA 42/105 (40%) 127/295 (43.1%) 1.7 0.22 0.73–3.99
AA 56/105 (53.3%) 136/295 (46.1%) 1.34 0.2 0.85–2.09
CELA3B Nucleotide Change Genotype ICP Patients Controls OR p Value 95% CI
Intron 6 c.643-7G>T
GG 70/105 (66.7%) 185/293 (63.1%) – – –
GT 31/105 (29.5%) 91/293 (31.1%) 0.86 0.52 0.54–1.37
TT 4/105 (3.8%) 17/293 (5.8%) 0.64 0.44 0.21–1.96
Exon 7 c.780T>C
TT 0/105 (0%) 0/293 (0%) – – –
TC 2/105 (1.9%) 6/293 (2%) – – –
CC 103/105 (98.1%) 287/293 (98%) 1.08 0.93 0.21–5.42
Intron 7 c.795+21C>A
CC 3/105 (2.8%) 24/293 (8.2%) – – –
CA 43/105 (41%) 125/293 (42.7%) 3.03 0.08 0.89–10.29
AA 59/105 (56.2%) 144/293 (49.1%) 1.33 0.22 0.85–2.08
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2.2. Functional Analysis of Missense Variants and the Gene Conversion Event
To characterize how missense mutations in CELA3A and CELA3B and the gene conversion
in CELA3B alter elastase secretion and activity, we transfected human embryonic kidney (HEK)
293T cells with expression plasmids and measured proelastase levels in the conditioned medium
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and elastase activity by
enzymatic assays. When elastase secretion into the medium was determined at 48 h after transfection,
all variants were secreted normally, as judged by Coomassie Blue staining and densitometry of
stained gels (Figure 2). CELA3B variant p.V232L exhibited a slight (~20%) but reproducible increase
in secretion. Similarly, elastase activity of the conditioned medium after activation with trypsin
showed no major differences among the variants and wild-type enzymes when measured with the
Suc-Ala-Ala-Pro-Ala-p-nitroanilide chromogenic peptide substrate (Figure 3). Consistent with its
increased levels of secretion, variant p.V232L exhibited higher activity while the activity of the gene
conversion variant (p.T246F, p.R247I, p.R248W) was slightly (1.4-fold) reduced relative to wild-type
CELA3B. Interestingly, variants p.G241A in CELA3A and p.A241G in CELA3B had opposite effects on
elastase activity. Thus, activity of the CELA3A p.G241A variant was increased by 1.8-fold, whereas
activity of the CELA3B p.A241G variant was decreased by 2.2-fold relative to their respective wild-type
controls. Even though these changes in activity controlled by the amino acid at position 241 (Gly
versus Ala) are intriguing mechanistically, they have no impact on CP risk as demonstrated by the lack
of genetic association described above.
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Figure 2. Secretion of CELA3A and CELA3B variants. Human embryonic kidney (HEK) 293T cells were
transfected with the indicated constructs and conditioned medium was collected 48 h after transfection.
Levels of secreted proelastases were determined by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and Coomassie Blue staining as described in Materials and Methods.
(A) Densitometric quantitation of secreted CELA3A and CELA3B. Average values from three transfections
with standard deviation (S.D.) are indicated; expressed as percent of wild-type levels; (B) Representative
gels are shown with samples loaded in duplicate. The molecular mass markers were PageRuler
Prestained Protein Ladder (Thermo Scientific, Waltham, MA, USA; PI-26616). The arrow indicates
the proelastase bands. The diffuse appearance of the CELA3B bands is likely due to N-glycosylation.
TRR-FIW designates the p.T246F, p.R247I, p.R248W variant which is the product of the gene conversion.
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Figure 3. Activity of CELA3A and CELA3B variants in the conditioned medium of transfected HEK
293T cells. Proelastases were activated with trypsin and elastase activity was determined as described
in Materials and Methods. Average values ± S.D. from three transfections are shown. TRR-FIW
designates the p.T246F, p.R247I, p.R248W variant which is the product of the gene conversion.
3. Discussion
In the present study we tested the hypothesis that changes in complex formation between human
proelastases and procarboxypeptidases might alter risk for CP. We speculated that individual variations
in the levels of these zymogen complexes may influence digestive enzyme activation as the free,
uncomplexed enzyme should be more susceptible to activation than its complexed form. Indeed,
we recently demonstrated that activation of human procarboxypeptidases A1 and A2 were delayed
when bound to human proCELA3B [11]. Although activation of proCELA3B did not seem to be directly
affected by complex formation, changes in folding, solubility, packaging and secretion might be altered
which can ultimately promote ectopic elastase activation inside the pancreas. To identify whether such
mechanisms play a role in CP risk, we took advantage of the observation that the primary amino-acid
determinants of complex formation in CELA3A and CELA3B are polymorphic in the population. Thus,
normally proCELA3A binds poorly to procarboxypeptidases due to the presence of Gly241, whereas
proCELA3B which contains Ala241 forms tight complexes [11]. Individuals carrying a heterozygous
p.G241A mutation in CELA3A should have increased complex levels in their pancreatic secretions.
Conversely, subjects with the p.A241G variant in CELA3B should exhibit decreased complex formation
and higher levels of free zymogens. Should CP risk be elevated by decreased complex formation,
one would expect to observe underrepresentation of the CELA3A p.G241A variant and/or enrichment
of the CELA3B p.A241G variant in a cohort of CP patients versus population controls.
To determine allele frequencies of these variants, we sequenced exon 7 and flanking intronic
regions of CELA3A and CELA3B in CP patients and controls of Hungarian origin. We found that allele
frequencies of CELA3A p.G241A and CELA3B p.A241G were not significantly different between the
two groups, indicating that these variants do not alter CP risk. Despite the lack of statistical significance,
an opposing trend for enrichment of the two variants was apparent. Thus, CELA3A variant p.G241A
was slightly overrepresented in controls while CELA3B variant p.A241G was overrepresented in
patients. Assuming the OR values represent the true effect sizes, we would need a much larger cohort
to confirm these findings with statistical significance. These effects, on the other hand, would be still
clinically insignificant, which does not justify further extension of the studies.
In addition to the position 241 variants discussed above, we identified six synonymous variants,
two missense variants, a gene conversion event and ten variants in the flanking intronic regions.
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Intriguingly, CELA3B variant c.643-7G>T in intron 6 was significantly underrepresented in ACP
patients, indicating an approximately 1.7-fold protective effect against CP. This variant is located
relatively close to the pre-mRNA splice site and it is conceivable that it might disrupt splicing and
decrease CELA3B expression. This finding suggests that elastase activity contributes to pancreatitis
risk and warrants extension of sequence analysis of the CELA3A and CELA3B genes and replication of
the observed association(s) in an independent cohort. None of the other variants showed a significant
difference in frequency between CP patients and controls. Finally, we performed functional analysis
on all missense variants detected in this study and found no major defects in proelastase secretion or
elastase activity.
We discovered a rare gene conversion event between exons 7 of CELA3A and CELA3B in an
individual with ICP. Gene conversion is a non-reciprocal exchange of genetic information between
homologous DNA sequences, most likely as a result of mismatch repair following a heteroduplex
formation between the donor and acceptor genes [18]. DNA exchange by gene conversion is of
paramount importance for the evolution of gene families but it can also cause human diseases [18]
including CP and other pancreatic pathologies. Gene conversion events between PRSS1 and PRSS2
or between PRSS1 and the pseudogene PRSS3P2 were shown to generate pathogenic alleles that
cause hereditary pancreatitis [19–21]. More recently, a recombination allele of the carboxyl ester
lipase gene (CEL) and its pseudogene CELP was described as a novel genetic risk factor for CP [22].
Finally, conversion events between the SBDS gene and its paralogous duplicated pseudogene SBDSP
cause Shwachman-Bodian-Diamond syndrome, an autosomal recessive disorder with pancreatic
exocrine insufficiency, hematologic dysfunction, and skeletal abnormalities [23]. The newly found
gene conversion event between CELA3A and CELA3B was detected in a CP patient, however, this is
likely an accidental finding as we found no functional defect with respect to secretion or activity of the
converted CELA3B that might suggest a pathogenic role in CP.
In summary, our study demonstrated that variants affecting amino-acid position 241 in human
CELA3A and CELA3B are not associated with CP, indicating that changes in complex formation between
human proelastases and procarboxypeptidases do not influence the risk for CP. The observation that
intronic variant c.643-7G>T in CELA3B was significantly underrepresented in ACP patients suggests
this might be a protective variant.
4. Materials and Methods
4.1. Nomenclature
Nucleotide numbering reflects coding DNA numbering with +1 corresponding to the A of the
ATG translation initiation codon in the CELA3A and CELA3B reference sequences (Homo sapiens
chromosome 1, GRCh38.p2 primary assembly, NC_000001.11). Note that the reference sequence for
CELA3A contains the minor alleles at positions c.722 (p.241) and c.795+21. Similarly, in CELA3B
positions c.780 (p.260) and c.795+21 represent minor alleles. To better contrast position 241 between
the two genes, we used the major c.722G allele (p.G241) as a reference for CELA3A and designated the
variant at this position as c.722G>C (p.G241A). Amino-acid variants are numbered starting with the
initiator methionine of the primary translation products of CELA3A and CELA3B.
4.2. Study Subjects
De-identified genomic DNA samples were obtained from the registry of the Hungarian Pancreatic
Study Group (ethical approval: TUKEB 22254-1/2012/EKU, biobanking approval: IF702-19/2012).
Individuals in the registry were recruited from 11 Hungarian centers between 2012 and 2016 and all
gave informed consent according to the ethical guidelines of the Declaration of Helsinki. The study
was approved by the Institutional Review Board at Boston University (“Analysis of susceptibility
genes in patients with chronic pancreatitis”; IRB number H-35382). A total of 225 unrelated patients
with CP, including 120 with alcoholic CP (ACP) and 105 with idiopathic CP (ICP) and 300 control
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subjects with no pancreatic disease were studied. Sequence analysis of CELA3A and CELA3B was
successfully completed for 295 and 293 of the 300 control samples, respectively. Patient characteristics
are summarized in Table 7. Diagnosis of CP was based on two or more of the following findings:
history of recurrent acute pancreatitis, pancreatic calcification detected by CT or ultrasonography,
and pancreatic ductal irregularities on endoscopic retrograde cholangiopancreatography (ERCP) or
magnetic resonance cholangiopancreatography (MRCP) examinations. ACP was diagnosed when the
patient history included alcohol consumption of more than 80 g/day (men) or 60 g/day (women) for at
least two years. ICP was diagnosed in the absence of precipitating or risk factors for pancreatitis, such
as alcohol abuse, medications, trauma, metabolic disorders or infection. A representative sample of
this cohort including 100 patients (49 ACP and 51 ICP) and 100 controls was previously characterized
for the clinically common SPINK1 variants; the p.N34S variant was found in three ICP patients and in
one control subject while the c.194+2T>C variant was detected in two ACP and one ICP patients but
not in controls [24].
Table 7. Study population. Age represents age at recruitment. Mean ± S.D. are shown. CP: chronic
pancreatitis.
ACP n = 120 ICP n = 105 All CP n = 225 Controls n = 300
Male Female Male Female Male Female Male Female
107 13 63 42 170 55 180 120
Age 56 ± 9 51 ± 8 58 ± 12 61 ± 14 57 ± 11 59 ± 14 52 ± 11 52 ± 13
Age of onset 47 ± 11 46 ± 9 49 ± 12 52 ± 17 48 ± 11 50 ± 16 – –
4.3. DNA Sequencing
Primers were designed against intronic sequences flanking exon 7 in CELA3A and CELA3B.
Primer sequences and amplicon sizes are given in Table 8. Polymerase chain reactions (PCR) were
performed using 0.75 U HotStar Taq DNA polymerase (Qiagen, Valencia, CA, USA), 0.2 mM dNTP,
5 µL 5× Q-solution and 2.5 µL 10× PCR buffer (Qiagen), 0.5 µM primers, and 10–50 ng genomic
DNA template in a volume of 25 µL. PCR reactions were started by a 15-min initial heat activation at
95 ◦C followed by 35 cycles of 30 s denaturation at 94 ◦C, 30-s annealing at 55 ◦C, and 40 s extension
at 72 ◦C; and finished by a final extension for 5 min at 72 ◦C. Products of all PCR reactions were
verified by 2% agarose gel electrophoresis. The PCR amplicons (5 µL) were treated with 1 µL FastAP
Thermosensitive Alkaline Phosphatase and 0.5 µL Exonuclease I (Thermo Fisher Scientific, Waltham,
MA, USA) for 15 min at 37 ◦C and the reaction was stopped by heating the samples to 85 ◦C for 15 min.
Sanger sequencing was performed using the reverse PCR primer as sequencing primer. Amplicons
containing heterozygous deletion variants in intron 6 of CELA3A were also sequenced with the forward
PCR primer. New variants were confirmed by a second independent PCR amplification and also by
sequencing the other DNA strand.
Table 8. Oligonucleotide primers used for PCR amplification of exon 7 in CELA3A and CELA3B.
Primer Sequence (5′→ 3′) Amplicon Annealing Temperature
CELA3A x7 Forward TCA GAG GTG TCA AGT AAT GTC AG 461 bp 55 ◦CCELA3A x7 Reverse CTT GAT GGC TTC TGG GTG G
CELA3B x7 Forward TCA GAG GAG TCA GGT AAT GTC G 484 bp 55 ◦CCELA3B x7 Reverse AAG TTC AGC TGT AGT TCC AAG C
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4.4. Plasmid Construction and Mutagenesis
Construction of expression plasmids for human CELA3A and CELA3B carrying C-terminal His
tags in the pcDNA3.1(−) vector was described previously [11]. Mutations were introduced by overlap
extension PCR mutagenesis.
4.5. Cell Culture and Transfection
Human embryonic kidney (HEK) 293T cells were cultured in 6-well tissue culture plates at a
density of 106 cells per well in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Scientific)
supplemented with 10% fetal bovine serum, 4 mM glutamine, and 1% penicillin/streptomycin at
37 ◦C in a humidified atmosphere containing 5% CO2. Transfections were performed using 4 µg
expression plasmid and 10 µL Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in 2 mL DMEM.
After overnight incubation at 37 ◦C, cells were rinsed and overlaid with 2 mL Opti-MEM reduced
serum medium (Gibco). Media and cells were collected 48 h after this medium change.
4.6. Measurement of Elastase Activity in Conditioned Media
Aliquots (100 µL) of conditioned media were supplemented with 0.1 M Tris-HCl (pH 8.0) by
adding 10 µL from a 1 M stock solution and 1 mM calcium by adding 1 µL of a 0.1 M CaCl2 solution.
Proelastases were activated with 100 nM human cationic trypsin (final concentration) for 30 min at
37 ◦C. Aliquots (20 µL) of activated elastases were then mixed with 175 µL assay buffer (0.1 M Tris-HCl
(pH 8.0), 1 mM CaCl2, 0.05% Tween 20) and elastase activity was measured by adding 5 µL of 6 mM
Suc-Ala-Ala-Pro-Ala-p-nitroanilide substrate. The release of the yellow p-nitroaniline was followed at
405 nm in a SpectraMax Plus384 microplate reader (Molecular Devices, Sunnyvale, CA, USA) for 5 min.
Rates of substrate cleavage were calculated from fits to the initial linear portions of the curves and
expressed in milliOD/min units.
4.7. SDS-PAGE
Conditioned media (180 µL) were precipitated with 10% trichloroacetic acid (final concentration);
the precipitate was collected by centrifugation and resuspended in 20µL Laemmli sample buffer containing
100 mM dithiothreitol, heat-denatured at 95 ◦C for 5 min and run on 15% SDS-polyacrylamide gels.
The gels were stained with Coomassie Blue R-250. Densitometric quantitation of bands was carried out
with the Gel Doc XR+ gel documentation system and Image Lab software (Bio-Rad, Hercules, CA, USA).
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